Coherus Oncology (CHRS) EPS (Basic) (2013 - 2026)
Coherus Oncology's (CHRS) quarterly EPS (Basic) came in at -$0.13 in Q2 2026, down 105.19% year-over-year from $2.57 in Q2 2025, and up 52.58% quarter-over-quarter from -$0.28 in Q1 2026.
Powered by 
Analysis
Coherus Oncology (CHRS) EPS (Basic) (2013 - 2026) Analysis & Trends
Coherus Oncology has disclosed EPS (Basic) across 14 years of filings, most recently posting -$0.13 for Q2 2026.
- In Q2 2026, EPS (Basic) fell 105.19% year-over-year to -$0.13; the TTM figure through Jun 2026 stood at -$0.85 (down 155.11% YoY), while the FY2025 annual figure was $1.76, up 173.82% from the prior year.
- EPS (Basic) came in at -$0.13 for Q2 2026 at Coherus Oncology, up from -$0.28 in the prior quarter.
- In the past five years, EPS (Basic) ranged from a high of $2.57 in Q2 2025 to a low of -$1.24 in Q1 2022.
- Average EPS (Basic) over 5 years is -$0.29, with a median of -$0.42 recorded in 2023.
- The largest YoY upside for EPS (Basic) was 2379.55% in 2025 against a maximum downside of 227.59% in 2025.
- Over 5 years, EPS (Basic) stood at -$0.76 in 2022, then slipped by 11.55% to -$0.85 in 2023, then surged by 47.68% to -$0.44 in 2024, then rose by 27.39% to -$0.32 in 2025, then surged by 58.53% to -$0.13 in 2026.
- Per Business Quant data, the three most recent EPS (Basic) figures were -$0.13 in Q2 2026, -$0.28 in Q1 2026, and -$0.32 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 4.40 |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -8.44 |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 4.34 |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 12.62 |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 7.70 |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -1.96 |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 1.23 |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 0.66 |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -0.40 |
| 10 | Coherus Oncology | 209.00 Mn | 103.70 Mn | 10.07 Mn | -0.13 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -0.13 |
| Mar 31, 2026 | -0.28 |
| Dec 31, 2025 | -0.32 |
| Sep 30, 2025 | -0.31 |
| Jun 30, 2025 | 2.57 |
| Mar 31, 2025 | -0.49 |
| Dec 31, 2024 | -0.44 |
| Sep 30, 2024 | -0.09 |
| Jun 30, 2024 | -0.11 |
| Mar 31, 2024 | 0.91 |
| Dec 31, 2023 | -0.85 |
| Sep 30, 2023 | -0.41 |
| Jun 30, 2023 | -0.49 |
| Mar 31, 2023 | -0.96 |
| Dec 31, 2022 | -0.76 |
| Sep 30, 2022 | -1.11 |
| Jun 30, 2022 | -0.65 |
| Mar 31, 2022 | -1.24 |
| Dec 31, 2021 | -0.61 |
| Sep 30, 2021 | -0.49 |